CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Fenofibrate +1 moredrug
Likely dose
Fenofibrate 145 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05080192
NCT05080192N/ACompleted
CompareCT.gov

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of Fenofibrate

University of Pennsylvania·observational·Posted Oct 15, 2021·Updated Jun 21, 2024

In Brief

An observational study evaluating Fenofibrate and Placebo for Covid19. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 15, 2021
Enrollment StartAug 11, 2021
Primary CompletionMay 10, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.7 years ago

Interventions

Fenofibratedrug

145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)

Placebodrug

Matching placebo (once/day) for 10 days